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Abstract
Fragile X syndrome (FXS) is a monogenic form of intellectual disability and autism spectrum disorder caused by the absence
of the fragile X mental retardation protein (FMRP). In biological models for the disease, this leads to upregulated mRNA
translation and as a consequence, deficits in synaptic architecture and plasticity. Preclinical studies revealed that
pharmacological interventions restore those deficits, which are thought to mediate the FXS cognitive and behavioral
symptoms. Here, we characterized the de novo rate of protein synthesis in patients with FXS and their relationship with
clinical severity. We measured the rate of protein synthesis in fibroblasts derived from 32 individuals with FXS and from 17
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controls as well as in fibroblasts and primary neurons of 27 Fmr1 KO mice and 20 controls. Here, we show that levels of
protein synthesis are increased in fibroblasts of individuals with FXS and Fmr1 KO mice. However, this cellular phenotype
displays a broad distribution and a proportion of fragile X individuals and Fmr1 KO mice do not show increased levels of
protein synthesis, having measures in the normal range. Because the same Fmr1 KO animal measures in fibroblasts predict
those in neurons we suggest the validity of this peripheral biomarker. Our study offers a potential explanation for the
comprehensive drug development program undertaken thus far yielding negative results and suggests that a significant
proportion, but not all individuals with FXS, may benefit from the reduction of excessive levels of protein synthesis.
Introduction
Adaptations of synaptic strength to neuronal activity are
thought to be cardinal in learning and memory (1). Synaptic
integrity is compromised in many neurodevelopmental disor-
ders including broad clinical categories such as intellectual dis-
abilities (IDs), autism and schizophrenia as well as specific
monogenic or monolocus forms of IDs and autism such as
tuberous sclerosis, 16p11.2 deletion and fragile X syndrome
(FXS) (2–4). The latter is caused by the loss of function of FMR1
and subsequent lack of the resulting protein FMRP (5). One of
the molecular mechanisms regulating spine shaping is local
dendritic protein synthesis that affords spatial and temporal
regulation of gene expression enabling synapses to autono-
mously alter their structure and function (6–8). FMRP is crucial
in regulating this process and partial or complete lack of FMRP
leads to an increase in protein translation at synapses (9–12).
The metabotropic glutamate receptor subtype 5 (mGluR5)
theory of FXS posits that imbalance of mechanisms involved in
protein translation and synaptic shaping is driving many of the
symptoms observed in patients with FXS (13). Compelling data
shows that altered mechanisms regulating levels of protein
synthesis, as well as cognitive and behavioral symptoms, can
be restored by reducing mGluR5 signaling genetically or with
pharmacological treatments in mouse and fly models of FXS
(Fmr1 KO) (14–18). Furthermore, pharmacological or peptide-
based interventions can partially or fully restore appropriate
rates of de novo protein synthesis as well as synaptic architec-
ture and plasticity. These include several mGluR5 antagonists,
gamma-butyric acid (GABAB) agonists, statins, lithium and ribo-
somal protein tyrosine kinase S6 (S6K) inhibitors. Genetic inter-
ventions [including mGluR5 reduction by haplo-insufficiency,
striatal enriched tyrosine phosphatase (STEP) signaling reduc-
tion, MMP9 reduction and S6K signaling reduction] can also
restore these molecular and cellular phenotypes (14,19–34).
Recently it has been shown that mGluR-mediated increase of
protein synthesis is sustained by the excessive production of
soluble amyloid beta precursor protein a (sAPPa) due to the
impaired processing of amyloid beta precursor protein (APP)
during a critical developmental window (35). More importantly,
treatment of FXS mice with a cell permeable peptide able to
modulate ADAM metallopeptidase domain 10 (ADAM10) activ-
ity, and therefore APP processing, restores protein synthesis to
wild type (WT) levels and rescues behavioral deficits that consti-
tute a hallmark of the disease (35).
The above mentioned preclinical data led to the develop-
ment of one of the most comprehensive drug development pro-
grams undertaken thus far for a genetically defined group of
neurodevelopmental disorders. It was conducted in parallel by
several pharmaceutical companies, and academic research cen-
ters assessing the effect of mGluR5 antagonists, GABAA and
GABAB agonists in children, adults and adolescents with FXS.
Unfortunately, what appeared to be an optimal translational
scenario in FXS has not led to the expected results (36,37), and
none of the human studies have demonstrated yet efficacy in
children, adolescents or adults with FXS on the primary out-
come measures which were mainly behavioral questionnaires
(37–39). These sobering results have not deterred the commun-
ity and despite these setbacks, molecular mechanisms control-
ling protein synthesis continue to be the prime targets in FXS
and other neurodevelopmental disorders. This is illustrated by
several large and innovative ongoing clinical trials targeting
these mechanisms (www.clinicaltrial.gov). These ‘second gen-
eration’ trials attempt to avoid pitfalls potentially related to the
aforementioned negative results by enrolling younger patients,
using objective cognitive measures and biomarkers including
EEG and eye tracking (40,41). Dysregulated protein synthesis has
been observed in the animal models of FXS (42,43) and sug-
gested to be pathogenic in FXS. Altered protein synthesis in
human patients with FXS has only been investigated in a few
studies. In a study of immortalized lymphoblastoid cell lines
derived from one patient with FXS and one healthy control that
used a fluorescent metabolic labeling method to measure nas-
cent protein synthesis, higher rates of synthesis were observed
in patient-derived cells compared to control (44). In a L-
[1–11C]leucine positron emission tomography study, rates of
cerebral protein synthesis (rCPS) were found to be lower in 15
FXS individuals compared to 12 age-matched controls (45). This
unexpected finding, discordant with what is seen in the Fmr1
KO mice was interpreted as a side effect of propofol sedation
used in the study and subsequently shown to decrease rates of
protein synthesis in Fmr1 KO mice (45,46). A study based on
human fibroblasts derived from FXS patients focused on dem-
onstrating the relevance of fibroblasts as in-vitro model and in
particular, whether these cells can be used to evaluate drugs
prior to their use in clinical trials. Basal [3H]leucine incorpora-
tion rates in fibroblast lines derived from eight individuals with
FXS showed elevated rates of protein synthesis compared to
nine controls along with increased levels of phosphorylated
mechanistic target of rapamycin (p-mTOR). A similar trend
was observed in peripheral blood mononuclear cells (PBMCs)
derived from patients with FXS for phosphorylated extracellular
signal regulated kinase 1/2 (p-ERK 1/2) and phosphorylated p70
ribosomal S6 kinase 1 (p-S6K1) (46,47). Treatment with small
molecules that inhibit S6K1, and a known FMRP target, phos-
phoinositide 3-kinase (PI3K) catalytic subunit p110b, lowered
the rates of protein synthesis in both control and FXS fibroblasts
(44). The small sample size, and the lack of clinical data pre-
vented from investigating the distribution and variance of this
cellular trait as well as its relationship with clinical manifesta-
tions in humans. To which extent excessive protein synthesis is
associated with cognitive and behavioral impairments remains
unknown. The aim of the current study was to validate in
humans the protein synthesis findings obtained in the Fmr1 KO
mouse. We characterized the distribution of de novo rates of pro-
tein synthesis in patients with FXS using fibroblast cells. To
establish cross-tissue correlations, we performed in parallel,
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measures on fibroblasts and primary neurons from the same
Fmr1 KO mice. In addition, we investigated the relationship
between basal rates of protein synthesis and the severity of the
clinical symptoms in individuals with FXS.
Results
Fibroblasts from patients with FXS show variable levels
of protein synthesis
We characterized de novo protein synthesis in primary fibro-
blasts from 32 individuals with FXS (age range 6–69) in three
independent cohort datasets and from 17 controls (age range
from 10 to 50) described in the Supplementary Material,
Table S1. We have chosen the SUnSET assay based on puromy-
cin incorporation, as it has been shown to be a robust and accu-
rate method for measuring relative rates of protein synthesis in
cell culture (48). Fibroblasts derived from patients with FXS
were established at the University Hospital in Lausanne (FXS1),
at the Erasmus Medical Center in Rotterdam (FXS2) and at the
MIND Institute in Sacramento (FXS3). While within the control
group each individual presented a comparable level of protein
synthesis and very low technical and biological variability,
some patients with FXS presented very high rates of protein
synthesis (þ200% of the normal levels) and increased technical
and biological variability (Fig. 1A and B; and Supplementary
Material, Fig. S1A). We observed a 34% increase (corresponding
to a d-Cohen effect size of 0.48, non-parametric ANOVA
P¼ 0.0008) in the total level of de novo protein synthesis for the
FXS group (FXS 1þ 2þ 3, n¼ 32) compared to controls (n¼ 17). Of
note, a third of FXS patients showed rates within the normal
range (Fig. 1B). In particular, 21.9% of the FXS individuals dis-
played levels below the 50th percentile while 9.4% showed lev-
els between the 50th and the 90th percentile of the control
group. This variability was not explained by participant’s age,
gender or the number of cell passages. In particular, we
Figure 1. Global protein synthesis in human fibroblasts. (A) Quantification of puromycin incorporation normalized to Coomassie and Vinculin in control and FXS fibro-
blasts (FXS1, FXS2 and FXS3 cohort, respectively). Each dot represents the average of at least two independent experiments performed on successive cell passages per
individual. The bars represent the SEM; non-parametric ANOVA (n¼17 controls, n¼12 FXS1, n¼7 FXS2, n¼13 FXS3). (B) The panel shows multiple data points per indi-
vidual representing at least two independent experiments performed on successive cell passages (n¼17 controls, n¼32 FXS).
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conducted replicates to investigate the effect of multiple cell
passages on the level of protein synthesis, three measures were
performed for each cell line at the first, second and third pas-
sage (Supplementary Material, Fig. S2). A linear regression
excluded any correlation between the number of cell passages
and measures of de novo protein synthesis in the control group
(P¼ 0.40, non-parametric ANOVA) as well as in the FXS group
(P¼ 0.31, non-parametric ANOVA).
Levels of protein synthesis are not correlated to
measures of FMR1 expression
It has been largely shown that FMRP regulates the rate of pro-
tein synthesis by inhibiting translation, so the most straightfor-
ward hypothesis to explain the variability of protein synthesis
levels was differences in levels of FMRP (33,49,50). Indeed, indi-
viduals with fragile X syndrome present different levels of FMR1
methylation and mosaicism resulting in variable FMRP
expression (Fig. 2A and B; Supplementary Material, Table S2 and
Fig. S1B). As expected, we observed a higher FMRP levels (1.86
fold-increase) in the mosaic participants (P¼ 0.002) compared to
individuals with a full mutation without mosaicism. However,
FMRP levels in the FXS group did not show any correlation with
de novo protein synthesis (Pearson correlation coefficient 0.16,
P¼ 0.3789, Spearman correlation coefficient 0.18, P¼ 0.3052)
(Fig. 2C). All the parameters relative to FMR1 gene expression
were correlated among themselves, specifically: the status of
FMR1 promoter methylation in blood, FMR1 mRNA expression
in blood and fibroblasts, FMRP staining in lymphocytes
(Table 1). The lack of correlation between lymphocyte and fibro-
blast FMRP-related measures may be partially explained by the
use of two different techniques for the evaluation of FMRP level,
a semi-quantitative western blot for fibroblasts and a less accu-
rate and qualitative method based on the immunostaining for
lymphocyte (percentage of lymphocytes stained by FMRP anti-
bodies). Furthermore, this inconsistency may potentially be
affected by the level of intra tissue mosaicism. Indeed, Pretto
and colleagues described differences in methylation and size
mosaicism occurring between blood and fibroblasts in a cohort
of 18 FXS individuals (51).
Figure 2. FMRP levels in human fibroblasts. (A) FMRP levels normalized to Coomassie and Vinculin in control and FXS fibroblast groups. Each dot represents the average
of at least two independent determinations per individual. The bars represent the SEM; non-parametric ANOVA (n¼17 controls, n¼12 FXS1, n¼7 FXS2, n¼ 13 FXS3).
(B) In the panel each dot represents a single technical replicate (n¼ 17 controls, n¼32 FXS). (C) Correlation between FMRP levels and puromycin signals measured by
the SUnSET assay in fibroblast cultures from individuals with FXS.
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We did not observe any correlation between the levels of de
novo protein synthesis, FMR1 mRNA and FMRP protein levels in
blood as well as in fibroblasts. Furthermore, amongst the differ-
ent interactors of FMRP (52) we analyzed the expression level of
CYFIP1 (Cytoplasmic FMR1-interacting Protein1), a specific
translational regulator (10,53) and of eIF4E, a general regulator
of protein translation. We did not observe any change between
FXS and controls and no correlation was observed with the level
of protein synthesis (data not shown). This suggests that addi-
tional factors, independent from FMR1 gene expression, contrib-
ute to the variability of the rate of de novo protein synthesis in
individuals with fragile X syndrome.
Fmr1 KO neurons and fibroblasts show an upregulation
of de novo protein synthesis
To further explore the validity of our observations in human
fibroblasts and address the contribution of heterogeneous genetic
background and individual variability, we analyzed the level of
protein synthesis in 30 Fmr1 KO mice (27 MEFs and 30 neuronal
primary cultures), in two different isogenic backgrounds (C57BL/6J
and FVB.129P2) and with no expression of functional FMRP (54).
We monitored protein synthesis by the SUnSET analysis in
primary cortical neurons and mouse embryonic fibroblasts
(MEFs) of Fmr1 KO mice (Fig. 3; Supplementary Material, Fig.
S1C). As opposed to FXS in humans which is caused by a CGG
expansion, leading to variable epigenetic silencing and low
FMRP expression in mosaic cases, the knockout mouse com-
pletely lacks FMRP expression (54). Levels of puromycin incorpo-
ration were measured in independent neuronal cultures from
Fmr1 KO (n¼ 30) and WT mice (n¼ 21). In neurons, protein syn-
thesis levels were significantly increased (non-parametric
ANOVA, P¼ 0.0001) compared to WT (Fig. 3A), consistent with
previous findings (35). Of note, levels of puromycin incorpora-
tion measured in MEF from Fmr1 KO (n¼ 27) and WT (n¼ 20)
mice were increased as well (Fig. 3B) although the effect size
was smaller (non-parametric ANOVA, P¼ 0.0031). Interestingly,
in the FXS mouse model in which the expression of FMRP is
absent, measures in 17% of the neuronal lines and 19% of the
MEFs were within the normal range and showed a broad distri-
bution. This suggests again that variance in the dysregulation of
de novo protein synthesis is determined by factors likely inde-
pendent of FMRP.
To establish whether levels of de novo protein synthesis in
neurons could be predicted by those measured in fibroblasts,
we established a method for preparing primary neurons and
MEFs from the same animal. Puromycin incorporation was
measured in Fmr1 KO (n¼ 16) and WT (n¼ 11) mice (Fig. 4A–D;
Supplementary Material, Fig. S1C) showing a significant correla-
tion between basal measures performed in neurons and in
fibroblasts (Spearman correlation coefficient 0.54, P¼ 0.004).
This relationship was not linear and log-transformation of pur-
omycin levels in primary neurons was required to observe the
same level of correlation using Pearson’s method (0.46, P¼ 0.02).
As an exploratory aim, we investigated whether molecular
measures (including protein synthesis, FMRP levels and methyl-
ation status) may explain some of the variance in several clini-
cal measures including the Vineland subscales, the Vineland
composite score and the presence of an autism diagnosis. This
analysis was performed in the fragile X group only, since clinical
data was not available in the control group (Supplementary
Material, Table S3). The Vineland rather than IQ was used
because IQ measures show important floor effects on standar-
dized cognitive tests in low functioning individuals that are
normed primarily for the typically developing population, and
are thus unable to capture the variance in the severity among
individuals with FXS (55). The Vineland adaptive behavioral
scale (VABS) and the diagnosis of Autism were performed in 21
FXS individuals from the Sacramento and Lausanne cohorts
(Table 2). This represented 32 tests and results were Bonferroni
corrected. None of the clinical measures showed significant cor-
relation with one of the four molecular measures (Table 2).
Discussion
Despite intense efforts, there are still no therapies targeting the
core mechanisms of FXS. Significant studies have focused on res-
cuing protein synthesis-dependent synaptic plasticity in mouse
Table 1. Correlation between FMR1 gene expression and levels of protein synthesisa
FMR1 mRNA FMRP Protein Synthesis
Blood Fibroblasts Lymphocytes IHC Fibroblasts W Blot Fibroblasts
N¼ 20 N¼ 30 N¼ 20 N¼ 32 N¼ 32
FMR1 Methylation,
blood n¼20
R ¼ 0.90
P < 0.0001
NS R ¼ 0.56
P ¼ 0.024
NS NS
FMR1 mRNA,
blood
NS R ¼ 0.72
P ¼ 0.001
NS NS
FMR1 mRNA,
Fibroblasts
NS R ¼ 0.69
P ¼ 0.0001
NS
FMRP Lymphocytes
IHC
NS NS
FMRP Fibroblasts
W Blot
NS
aCorrelation analysis between protein synthesis measured in fibroblasts and different measures of FMR1 expression in blood, and fibroblasts from patients with FXS
(Pearson correlation test). Correlation analysis indicates that the same measures in blood do not correlate with those performed in fibroblasts. Measures of protein syn-
thesis in fibroblasts do not correlate with any of the other measures of FMR1 expression. Spearman correlation analysis (data not shown) does not change any of the
results reported in the Table 1. (NS¼Pearson and Spearman tests not significant).
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models of FXS by manipulating receptors that regulate FMRP sig-
naling and activity. Drugs targeting group 1 metabotropic gluta-
mate receptors (mGluR1, 5) and GABA receptors have shown very
promising results in preclinical studies but a series of large human
trials have failed to demonstrate any benefits of these drugs (36).
Like for other neurological and psychiatric disorders, clinical trials
in FXS and neurodevelopmental disorders have been hindered by
two related issues: a partial understanding of the mechanisms
and a lack of biomarkers measuring these mechanisms (41). In
this study, we investigated the relevance of basal levels of de novo
protein synthesis measured in peripheral tissue as a biomarker of
translational control, one of the most extensively studied func-
tions of FMRP.
Our observations show significantly increased levels of pro-
tein synthesis in FXS human fibroblasts and suggest that the
non-radioactive SUnSET assay provides a robust readout to
study molecular and clinical correlates in patients with FXS.
Importantly, protein synthesis levels are not increased in all
individuals with fragile X suggesting that compounds restoring
translational regulation may not be helpful in a substantial pro-
portion of patients who show normal levels of basal protein
synthesis. We also show that de novo protein synthesis meas-
ured in mouse fibroblasts are reasonably correlated with levels
measured in neurons of the same animal. This suggests that
peripheral measures of protein synthesis may serve as a rele-
vant biomarker of the mechanisms underlying this condition as
well as response to treatments aiming at restoring translational
control in FXS and in other other neurodevelopmental disorders.
Although, several studies demonstrated a correlation
between FMRP levels and clinical phenotypes, these correla-
tions were mainly driven by groups of patients with detectable
levels of FMRP such as mosaic males with unmethylated full
mutation (56). In our samples, FMRP did not correlate to VABS
likely do to the fact that patients presented a classic form of
fragile X with little or no expression of FMRP. In those cases, the
observed clinical variability was most likely due to additional
factors.
Mounting evidence suggests that aberrant synaptic protein
synthesis may be a major contributing mechanism underlying
many forms of neurodevelopmental disorders including those
caused by mutations in MECP2, TSC1, TSC2, CYFIP1, SYNGAP1 as
well as deletions of the 16p11.2 locus (57–61). Mechanisms regu-
lating protein synthesis will therefore continue to be important
targets in future preclinical and clinical studies. However, all of
these studies have been conducted in animal models and the
contribution of aberrant synaptic protein synthesis to the nature
and severity of symptoms in patients remains unknown. We pro-
vide the first evidence on a cohort of 32 patients that measures of
basal protein synthesis in fibroblast cell cultures are relevant
markers of this mechanism and that protein synthesis may
explain some of the variance in symptoms observed in patients.
Our most puzzling observation is that some individuals with
FXS and Fmr1 KO mice have normal levels of basal de novo pro-
tein synthesis in fibroblasts as well as in primary neurons. Of
note cell division is not a contributing factor to the observed
variability since primary neurons are non-dividing cells. This
suggests, therefore, that this alteration may not be responsible
of all symptoms observed in patients and that individuals with
normal levels of protein synthesis would not benefit from drugs
that further decrease these levels. We recently observed in the
FXS murine model (Fmr1 KO) that the absence of FMRP leads to
a dysregulation in the anabolic pathway of the amyloid precur-
sor protein (APP). The exaggerated production of the APP proc-
essing metabolite sAPPa contributes to the three major
hallmarks of FXS: increased protein synthesis, aberrant spine
morphology and altered synaptic function and behavior (35).
While this study analyzed a large collection of primary cells
from patients and controls, the potential correlations between
increased levels of protein synthesis and clinical measures is
limited by the sample size. As an example, previous studies
Figure 3. Levels of protein synthesis in mouse primary neurons and embryonic fibroblasts. (A) Puromycin incorporation in primary neurons from WT and Fmr1 KO
mice normalized to Coomassie and Vinculin. Each dot represents the average of at least two technical replicates per animal. The bars represent the SEM; non-paramet-
ric ANOVA (WT n¼ 21; Fmr1 KO n¼30). (B) Puromycin incorporation in MEF from WT and Fmr1 KO mice, normalized to Coomassie and Vinculin. Each dot represents
the average of at least two technical replicates per animal. The bars represent the SEM; non-parametric ANOVA (WT n¼20, Fmr1 KO n¼ 27).
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have shown correlations between FMRP levels and cognitive
traits in 144 families with FXS, (56) as well as FMRP and autistic
traits in 83 FXS individuals (62). It is likely that the net increase
of protein synthesis in fragile X syndrome is not capturing the
complexity of translational dysregulation caused by the lack of
FMRP. In particular, it is unknown to which extent FXS may be
due to broad translational dysregulation as opposed to abnor-
mal regulation of a few transcripts.
In conclusion, protein synthesis remains a primary mecha-
nism for neurodevelopmental disorders and FMRP clearly
modulates this cellular phenotype but it is likely that many
other molecular factors independent of FMRP (environmental
and genetic) contribute to the modulation of homeostasis of
molecules involved in synaptic plasticity. Our findings demon-
strate that only a subgroup of individuals with FXS shows a
net increase in protein synthesis and this may serve to stratify
future clinical trials aiming at restoring translational
regulation.
Materials and Methods
Participants
The participants were enrolled in three independent hospitals/
centers [Department of Clinical Genetics, University Hospital
of Lausanne, Switzerland, Medical Investigation of Neurodeve-
lopmental Disorders (MIND) Institute, University of California,
Davis Medical Center, Sacramento, US and Department of
Clinical Genetics, Erasmus Medical Center, the Netherlands].
Demographics are summarized in Supplementary Material, Table S1.
Lausanne cohort (FXS 1)
Inclusion criteria: Subjects were male, aged 12–45 years, with a
confirmed diagnosis of FXS based on genetic testing (full muta-
tion,>200 CGG repeats). They were required to have a Clinical
Global Impressions of Severity (CGI-S) score of4 (moderately
ill) and a score of20 on the ABC-C scale (at screening,
Figure 4. Levels of protein synthesis in matched mouse primary neurons and embryonic fibroblasts. Puromycin incorporation in neurons (A and B) and MEF (C and D)
derived from the same animal. In A and C, each dot represents the average of at least two technical replicates per animal. Bars represent the SEM; non-parametric
ANOVA (WT n¼11; Fmr1 KO n¼16). B and D show multiple data points per each animal (independent replicates).
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Supplementary Material, Table S1). Exclusion criteria: Clinically
significant systemic illness or symptoms that might deteriorate
or affect their safety or ability to cooperate during the study.
Subjects were required to list all concomitant medications
taken prior to the start of the study. The study protocol and all
amendments were reviewed by the Independent Ethics
Committee of the University hospital of Lausanne. Informed
written consent was obtained from each parent/legal guardian
as well as the participant.
Rotterdam cohort (FXS 2)
The study protocol and all amendments were reviewed by the
Independent Ethics Committee of the Erasmus Medical Center,
Rotterdam, The Netherlands.
Sacramento cohort (FXS 3)
All participants signed one or more consents for the collection
of a blood sample, skin biopsy and fibroblast culture. They were
enrolled in clinical studies assessing the phenotype and geno-
type correlations. Inclusion criteria: Confirmed diagnosis of FXS
with a FMR1 full mutation (>200 CGG repeats) with or without a
mosaic status (Supplementary Material, Table S1). Subjects
were male, aged 12–69 years (inclusive). At screening, the medi-
cal history was reviewed and the study eligibility according to
the inclusion and exclusion criteria was assessed according to
which study they were enrolled. Biological specimens were col-
lected at day 1 and the FXS phenotype was assessed either at
Day 1 or at Day 2, if the subject could not complete all the tests
in one day. The study protocol and all amendments for each
study were reviewed by the Institutional Review Board of the
University of California Davis Medical Center. Informed written
consent was obtained from each parent/legal guardian as well
as the participant assent.
Clinical assessments
Clinical assessments were available for the Sacramento and the
Lausanne cohort. No phenotypic data were available for the
Rotterdam samples (FXS2). Controls (cell lines from the bio-
banks of Coriell Institute for Medical Research, CliniSciences,
Lonza) were not clinically assessed. Clinical assessments are
summarized in Supplementary Material, Tables S1 and S3. All
participants from the Sacramento cohort had IQ testing per-
formed using the Stanford-Binet Intelligence Scales, Fifth
Edition (SB-5), (63) the Wechsler Preschool and Primary Scale of
Intelligence, third edition (WPPSI 3) (64) or the Wechsler Adult
Intelligence Scale-Third Edition (WAIS 3) (65). For the partici-
pants from the Lausanne cohort a mental age was calculated
based on the scores from the Wechsler nonverbal scale or
WPPSI, Wechsler preschool and primary scale of intelligence.
Adaptive functioning was measured using the Vineland
Adaptive Behavior Scales, Second Edition (66) A diagnosis of
Autism Spectrum Disorder was established by the Autism
Diagnostic Observation Schedule (ADOS) Module 3 or Module 4
(67,68).
Primary human fibroblasts
The cell lines analyzed in this study are listed in Supplementary
Material, Table S2. The control fibroblasts were derived from
individuals who were free of any neurological disease (n¼ 17,
age range 10–50 years inclusive) and were purchased from the
Coriell Cell Repositories (Camden, NJ), LONZA and Cliniscience
supplier and provided by the UZ Leuven biobank (n¼ 3). The
human male FXS fibroblasts (n¼ 32, age range 6–69 years inclu-
sive) were derived at the Cytogenetics Department, University
Hospital of Lausanne (FXS1), MIND Institute Fragile X Research
and Treatment Center, UC DAVIS (FXS3), Department of
Neurosciences, Erasmus MC, Rotterdam (FXS2).
Fibroblasts were prepared from dermal biopsies obtained
from individuals with a confirmed diagnosis of FXS based on
clinical features of the disease, expression of FRAXA (fragile
site, X chromosome, A site), genetic testing (full mutation,>200
CGG repeats). 17 subjects had a hypermethylated FMR1 full
mutation while 15 subjects showed methylation or size mosai-
cism. Cells were maintained in DMEM F12 medium supple-
mented with 10% Fetal Bovine Serum, 1X GlutaMaxTM, 1X
Table 2. Correlation between the Vineland adaptive behavior scale, protein synthesis and FMRP related biomarkersa
Variable 1 Variable 2 Pearsons correlation Pp Spearman correlation Ps
Protein synthesis in patients with FXS (n ¼ 21) Vineland_Co 0.41 0.0618 0.51 0.0171
Vineland_DL 0.59 0.0046 0.68 0.0007
Vineland_S 0.44 0.0437 0.53 0.0128
Vineland_AB 0.28 0.2178 0.05 0.8360
FMRP levels in patients with FXS (n ¼ 21) Vineland_Co 0.01 0.9740 0.02 0.9220
Vineland_DL 0.26 0.2545 0.26 0.2465
Vineland_S 0.06 0.7841 0.05 0.8270
Vineland_AB 0.43 0.0543 0.44 0.0453
FMR1 mRNA levels (n ¼ 25) Vineland_Co 0.06 0.8173 0.23 0.3468
Vineland_DL 0.28 0.2526 0.52 0.0220
Vineland_S 0.15 0.5402 0.33 0.1683
Vineland_AB 0.36 0.1251 0.34 0.1535
FMR1 methylation levels (n ¼ 15) Vineland_Co 0.06 0.8553 0.33 0.2887
Vineland_DL 0.42 0.1761 0.59 0.0442
Vineland_S 0.22 0.4937 0.50 0.0971
Vineland_AB 0.71 0.0099 0.64 0.0255
aVineland Co (Communication), DL (Daily Living), S (Socialization), AB (Adaptive Behavior). Data on motor skills was not recorded for all cohorts. Spearman correlation
scores are similar across subscales except for abnormal behavior. The regression analysis did not show any main effect of age or cohort. The threshold for significance
is calculated at 0.0015 on the basis of 32 tests. No clear correlations are identified.
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Penicillin-Streptomycin (Life Technologies) and Mycozap
reagent (LONZA). FXS (n¼ 32) and controls (n¼ 17) fibroblast cell
lines were analyzed for expression levels of FMR1 mRNA and
FMRP at University of Rome Tor Vergata (Supplementary
Material, Table S2). A subset of these samples was also analyzed
in parallel at UC Davis.
Methylation status
Genomic DNA from primary fibroblast cell lines was isolated
using Gentra Puregene Blood Kit (Qiagen). CGG repeat allele size
and methylation status were obtained using a combination of
PCR and Southern Blot analysis as previously described (69–71).
FMR1mRNA levels in fibroblasts
Measurements of FMR1 mRNA expression levels were per-
formed by quantitative RT-PCR upon total RNA extraction from
control and FXS cells. Total RNA was isolated from the fibro-
blasts using TrizolTM reagent (Life Technologies) according to
manufacturer’s instructions. For the cDNA synthesis 500 ng of
total RNA was used as input into a 20 ll reaction using p(dN)6
and 200 U/ll M-MLV RTase (Invitrogen). FMR1 and hypoxanthine
phosphoribosyltransferase 1 (HPRT1) mRNAs were quantified by
real-time PCR using SYBRVR Green Master Mix (Bio-Rad) on
StepOnePlusTM Real-Time PCR machine (Life Technologies)
according to the manufacturer’s instructions. FMR1 mRNAs lev-
els were expressed in relative abundance compared to HPRT1
gene. Specific primers were used to amplify FMR1 and HPRT1
mRNAs:
FMR1: (50-TGT CAG ATT CCC ACC TCT TG-30; 50-TAA CCA
CCA ACA GCA AGG CT- 30)
HPRT1: (50-TGC TGA GGA TTT GGA AAG GGT-30; 50-TGC
AGC AAG ACG TTC AGT CC-30).
Obtained values were reported in Supplementary Material,
Table S2 using the hypoxanthine phosphoribosyltransferase 1
(HPRT1) mRNA as reference gene. Normalized relative quantities
(RQ) were calculated according to the method described by
Hellemans et al. (72). The arithmetic mean of the quantification
cycles (Cq) of all healthy normal volunteer samples was used as
a reference Cq for the calculation of RQ, FMR1 mRNA varied
between 0 and 2.88 (mean 0.64).
FMR1mRNA levels in blood samples
FMR1 mRNA expression levels in blood (cohort FXS1) were
measured by qRT-PCR. Complementary desoxyribonucleic acid
(cDNA) synthesis was performed using a high capacity cDNA
reverse transcription kit with RNAse Inhibitor (Applied
Biosystems, CA, USA). For the cDNA synthesis, 500 ng of
RNA was used as input into a 20 ll cDNA synthesis reaction to
generate 25 ng/ll cDNA (total RNA equivalents). RT-PCR
was performed using the ABI PRISMVR 7900HT Sequence
Detection System (Applied Biosystem). The following TaqMan
assays obtained from Applied Biosystems were used: FMR1:
Hs00924544_m1; actin B (ACTB): Hs99999903_m1; beta-
glucuronidase (GUSB): Hs99999908_m1. All samples were proc-
essed in triplicate with a 25 ng cDNA (total RNA equivalent) for
FMR1 and 10 ng cDNA (total RNA equivalent) for reference gene
assays (ACTB, GUSB). The RT-PCR consisted of one step at 50C
for 2 min, one denaturing step at 95C for 10 min followed by 40
cycles of melting (15 s at 95C) and annealing/extension (1 min
at 60C). Normalized relative quantities (RQ) were calculated
according to the method described by Hellemans et al. (72). The
arithmetic mean of the quantification cycles (Cq) of all healthy
normal volunteer samples was used as a reference Cq for the
calculation of RQ. RQ values were normalized using the geomet-
ric mean of the RQs of the two reference genes, ACTB and GUSB.
FMRP levels in different cell types
All fibroblast cell lines were analyzed by Western blotting. FMRP
levels in human fibroblasts were measured on total cell lysates
by Western blotting using a specific antibody against FMRP (73).
FMRP expression in blood was determined by immunostaining
of lymphocytes in blood smear using anti-FMRP antibody.
Briefly, blood smear slides were air-dried and fixed in acetone/
methanol (1:1) for 20 minutes at room temperature. After wash-
ing with phosphate buffered saline (PBS) solution followed by
reaction buffer (Tris-based buffer solution at pH 7.660.2,
Ventana Medical Systems, AZ, USA), the slides were loaded
onto the Ventana Discovery XT (Res IHC Omni-UltraMap HRP
XT); Ventana Medical System for anti-FMRP immunostaining,
following the auto-staining procedure. The blood smear slides
were fixed with acetone/methanol (1:1) and then treated with
the cell conditioning solutions, CC1 and CC2 (Ventana Medical
System) to allow the anti-FMRP monoclonal antibody (Millipore,
Billerica, MA, USA) to penetrate the lymphocyte cell membrane
and bind to FMRP. After washing the slides with reaction buffer
(Ventana Medical System), the anti-mouse secondary antibody
Omni-MapTM HRP (Ventana Medical System), the ChromoMap
DAB Hematoxylin II substrate (Ventana Medical System) and
the Blue reagent (Ventana) were added sequentially to visualize
the FMRP expression density and distribution. Quantification
was done measuring the % of cells expressing FMRP.
Animal experiments
All animal procedures were conducted conforming to institu-
tional guidelines in compliance with international laws and pol-
icies (European Community Guidelines for Animal Care, DL 116/
92, application of the European Communities Council Directive,
86/609/EEC). Studies were approved by the Institutional Ethical
Board at the University of Rome Tor Vergata, according to the
Guideline of the Italian Institute of Health (protocol n. 1088/
2016-PR). C57BL/6J and FVB.129P2 WT and Fmr1 KO male mice
(54) were used in this study.
Mouse neuronal cell cultures
Mouse primary cortical neurons were prepared as previously
described (74) from embryonic day (E) E15 mice. The brains were
removed, neocortices were freed of meninges, treated with
0.025% trypsin, minced and plated on poly-l-lysine (Sigma-
Aldrich) wells in Neurobasal medium supplemented with 2%
B27, 0.5 mM glutamine and Penicillin-Streptomycin (GIBCO
BRL); cells were maintained at 37C and 5% CO2. For the SUnSET
assay cells were seeded on 24 well plates and treated with puro-
mycin at DIV14. In a subset of experiments from the same
embryo, cortices were used for primary neurons and the rest for
the production of MEFs.
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Mouse embryo fibroblasts (MEFs) cultures
MEF cultures were prepared as previously described (75) from
embryonic day (E) E14–16 mice, by dissociation of the whole
embryo after removal of internal organs and heads. Embryos
were treated with 0.25% trypsin at 4C overnight, tissues minced
by pipetting up and down. Cells were plated on 6 well plate, 24 h
later the medium was replaced, cells were washed by shaking
vigorously twice to remove debris, detached cell clumps and
dead cells. Fresh media were added and cells were maintained
at 37C and 5% CO2 to reach confluence (2–3 days). At this stage
cells were frozen and used for later procedures. For the SUnSET
assay each culture was divided into 2 or 3 wells (cells were
plated in duplicate or triplicate in 12w-plate) and treated with
puromycin as described in the text.
SUnSET assay
A protein synthesis assay was performed as previously
described using the SUnSET method (48). Cells (80 000/well)
were seeded on 12-multiwell plate wells, deprived of serum for
16 h and after 4 h of recovery in complete medium supple-
mented with 10% FBS, were treated with puromycin 5 lg/ml for
30 min. To ascertain the specificity of the assay cells were pre-
incubated in the absence or presence of cycloheximide 60 mM
for 15 min. After puromycin pulse, cells were chased with fresh
complete medium for 15 min then washed with ice-cold PBS
and lysed directly in Laemmly buffer. Samples were analysed by
WB and puromycin incorporation was detected using the
mouse monoclonal antibody PMY-2A4. Coomassie staining of
total proteins and immunolabelling of housekeeping proteins
as GAPDH and Vinculin was used as loading control.
To assess the stability of measures within subjects, in addi-
tion to replicates performed by means of split passages per-
formed for all fibroblasts, independent SUnSET assays were
performed over a period of 1 year, on a subset of 10 cell lines fro-
zen, re-thawed and cultured again.
Western blotting
Standard methodologies were used. Protein extracts were sepa-
rated by SDS–PAGE electrophoresis, and transferred to a PVDF
membrane (GE Healthcare). Membranes were incubated using
specific antibodies including mouse anti-puromycin PMY-2A4
(1:500 DSHB), mouse anti-GAPDH (1:2000, Thermo Fisher),
mouse anti-Vinculin (1:2000, Sigma) and rabbit anti-FMRP
(1:1000) (73).
Secondary HRP-conjugated anti-rabbit, anti-mouse antibod-
ies (1:10 000) were purchased from Promega or Chemicon.
Proteins were revealed using an enhanced chemiluminescence
kit (Bio-Rad) and the imaging system LAS-4000 mini (GE).
Quantification was performed using the IQ ImageQuant TL soft-
ware (GE Healthcare). Coomassie staining of the membranes,
GAPDH and Vinculin signals were used as normalizers.
Statistical analysis
All statistical analyses were conducted using SAS. 9.3. A linear
regression was used to evaluate correlation between the num-
ber of cell passages and measures. A non-parametric analysis of
variance (ANOVA) was used to compare the differences of pro-
tein synthesis between groups. Correlation between molecular
levels and clinical parameters was accessed by Pearson and
Spearman correlation analysis.
Supplementary Material
Supplementary Material is available at HMG online.
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